GlassScriptPhysician profile
Allison T Murphy
NPI 1235656513
$3,468.18
in general payments reported to CMS, 2019-2025
36 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $157 · 2023: $980 · 2024: $904 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,192 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,191.65 |
| Education | $119.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $417.17 | 2023-2025 | |
| Daiichi Sankyo INC. | $409.14 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Merck Sharp & Dohme LLC | $373.07 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $268.08 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $247.70 | 2024-2025 | Lynparza, Enhertu |
| Glaxosmithkline, LLC. | $234.13 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Janssen Biotech, INC. | $152.66 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Genmab U.S., INC. | $143.11 | 2022-2023 | Tivdak |
| Mirati Therapeutics, INC. | $137.48 | 2023-2024 | Krazati |
| Astellas Pharma US INC | $122.02 | 2023-2025 | Xospata, Vyloy |
| Agios Pharmaceuticals, INC. | $90.26 | 2025 | Pyrukynd |
| Eisai INC. | $87.86 | 2023-2025 | |
| Csl Behring | $80.13 | 2022-2024 | Kcentra |
| Bayer Healthcare Pharmaceuticals INC. | $71.77 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $69.82 | 2023-2025 | Libtayo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $53.65 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Lilly USA, LLC | $51.64 | 2023 | Verzenio, Jaypirca, Retevmo |
| Tersera Therapeutics LLC | $51.00 | 2023 | Zoladex |
| Pharmaessentia USA Corporation | $49.38 | 2024 | Besremi |
| Emd Serono, INC. | $46.12 | 2023-2025 | Tepmetko |
| Aveo Pharmaceuticals, INC. | $38.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.18 | 2023 | Vpriv |
| Ge Healthcare | $20.85 | 2024 | |
| Boston Scientific Corporation | $20.78 | 2024 | Watchman Flx |
| Tempus Ai, INC | $20.15 | 2024 | Xt Cdx |
| Caris Mpi, INC. | $19.50 | 2025 | Mi Cancer Seek |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Karyopharm Therapeutics INC. | $17.41 | 2023 | Xpovio |
| Blueprint Medicines Corporation | $17.35 | 2023 | Ayvakit |
| Servier Pharmaceuticals LLC | $17.00 | 2024 | |
| Recordati_rare_diseases_inc. | $16.82 | 2024 | Sylvant |
| Alexion Pharmaceuticals, INC. | $16.81 | 2024 | Ultomiris |
| Stemline Therapeutics INC. | $16.55 | 2024 | Orserdu |
| Genzyme Corporation | $16.52 | 2025 | |
| Seagen INC. | $16.47 | 2023 | Tukysa |
| Pfizer INC. | $15.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.